Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Trading Statement

29 Jul 2021 07:00

RNS Number : 8142G
Dr. Martens PLC
29 July 2021
Β 

Β 

29 July 2021

Dr. Martens plc

Trading statement for the three months ended 30 June 2021

A STRONG FIRST QUARTER

"I am very pleased with the performance across our business in the first quarter of our new financial year. We achieved continued growth in ecommerce against a triple-digit growth rate last year and the reopening of our own-stores drove a strong retail recovery through the period. In addition, we saw a return to more normalised wholesale shipments over the period. The first quarter of the year is always our smallest period, being the end of the Spring/Summer season. Our larger Autumn/Winter season begins from Q2 and our performance to date gives us confidence for the remainder of the year. We will continue to take a long-term custodian mindset, investing into our business and making decisions to drive the brand for the decades to come." Kenny Wilson, Chief Executive Officer

Β 

Group highlights:

Β· Q1 Group revenue Β£147.3m, up 52% year on year (64% on a constant currency basis). This performance was against a Covid-19 impacted comparative figure, with revenues in the same quarter last year down 14%. On a two-year basis (Q1 FY22 compared to Q1 FY20), revenue was up 31% (40% constant currency). Q1 is typically the smallest period, being the end of the Spring/Summer season.

Β· By channel, we saw an encouraging recovery of retail, good growth in ecommerce against a very strong comparative and a strong wholesale performance as order patterns normalised.

Β· All three regions saw good growth, although the Americas was a standout, recording triple-digit revenue growth.

Β 

Channel performance

Throughout Q1 FY22, all US stores were open, UK stores opened from mid-April, and Continental Europe stores opened steadily through May and June. Japan remains the most impacted, with stores operating with varying capacity restrictions and a few locations remaining closed. This compares with Q1 last year, where the vast majority of our own stores globally were closed or subject to significant Covid-19 restrictions, which materially impacted retail revenues. This significantly altered picture has resulted in Q1 FY22 retail revenue more than tripling year-on-year. The performance of our stores improved as the quarter progressed, particularly those in the US and provincial UK. On a two-year basis (Q1 FY22 compared to Q1 FY20) performance was as expected, with retail revenue down 6% for the quarter as a whole and positive in the month of June.

In Q1 FY22, we achieved strong ecommerce revenue growth of 11% (19% on a constant currency basis). This was against a very high comparative with ecommerce growth in Q1 FY21 up triple-digit, given the widespread store closures at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), ecommerce revenue is up 155% (166% in constant currency terms).

We saw a very strong performance in our wholesale business in Q1 FY22, as customers normalised shipment timings back towards Q1. As a result, wholesale revenue is up 50% year-on-year (up 64% constant currency), with particularly strong shipments in Americas. This performance is against a weak comparative, as last year a large proportion of wholesale customers rescheduled orders into Q2 given the significant uncertainty at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), wholesale revenue is up 23% (30% in constant currency terms). Given the rescheduling of orders in FY21, we face a stronger comparative in Q2 and therefore expect wholesale sales growth to moderate.

Regional performance

The strongest regional performance was seen in Americas, with revenue up 106% (132% constant currency). This was predominantly driven by wholesale, with both a normalisation of shipments compared to the prior year and strong underlying growth. We also saw a good recovery in retail and continued ecommerce growth against a tough comparative.

EMEA delivered 30% revenue growth (36% constant currency). We saw an encouraging retail recovery as stores reopened, continued ecommerce growth against a very strong comparative, and good wholesale performance.

APAC saw revenues up 17% (30% constant currency), with good growth across all channels. The largest market in APAC is Japan, which continues to see significant Covid-19 restrictions in retail, albeit to a lower extent than last year.

Outlook

Trading in Q1 was slightly ahead of our expectations, with a strong end to the period. Q1 is by far the smallest quarter however, and in Q2 we face a much stronger comparative. We anticipate that the pattern of trading through the year will be non-linear and, like many others across the industry, we are experiencing inbound shipping delays and other operational challenges due to Covid-19. Despite these, we remain confident in the delivery of our guidance for FY22 and over the medium-term.

Β 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Media

Finsbury Glover HeringRollo Head, James Leviton +44 20 7251 3801

Gill Hammond, Director of Communications +44 7384 214248

Β 

Β 

FY21 Quarterly performance

The prior year quarterly revenue performance was as follows:

FY21

Q1

Q2

Q3

Q4

Group revenue (Β£m)

97.0

221.2

275.6

179.2

% yoy change (reported)

(14%)

42%

9%

19%

% yoy change (constant currency)

(14%)

43%

9%

23%

Β 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude.Β 

Β 

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTDKFBKABKDFOB
Date   Source Headline
8th Jun 202612:26 pmRNSHolding(s) in Company
5th Jun 202610:43 amRNSAdmission to Trading
2nd Jun 20269:00 amRNSDirector/PDMR Shareholding
2nd Jun 20269:00 amRNSAnnual Financial Report
2nd Jun 20268:22 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirectorate change
19th May 20267:00 amRNSEBT Share Purchase
19th May 20267:00 amRNSFY26 Results
14th May 20268:53 amRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSHolding(s) in Company
30th Apr 20268:31 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20269:50 amRNSDirector/PDMR Shareholding
10th Apr 20261:46 pmRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNS-RAppointment of Market General Managers
31st Mar 20269:53 amRNSTotal Voting Rights
20th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20262:03 pmRNSDirector/PDMR Shareholding
27th Feb 202611:04 amRNSTotal Voting Rights
13th Feb 202610:49 amRNSDirector/PDMR Shareholding
30th Jan 202611:15 amRNSTotal Voting Rights
29th Jan 20267:00 amRNSEBT Share Purchase
27th Jan 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSQ3 FY26 Trading Statement
15th Jan 20269:24 amRNSDirector/PDMR Shareholding
31st Dec 202511:11 amRNSTotal Voting Rights
31st Dec 202511:11 amRNSTotal Voting Rights
12th Dec 20253:00 pmRNSDirector/PDMR Shareholding
12th Dec 20257:00 amRNSDirector/PDMR Shareholding
8th Dec 20257:00 amRNSDirector/PDMR Shareholding
1st Dec 202512:35 pmRNSBlock listing Interim Review
28th Nov 202511:58 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20257:00 amRNSH1 FY26 Results
12th Nov 20252:13 pmRNSDirector/PDMR Shareholding
31st Oct 20252:37 pmRNSTotal Voting Rights
21st Oct 20256:16 pmRNSHolding(s) in Company
20th Oct 20254:06 pmRNSHolding(s) in Company
16th Oct 20252:12 pmRNSDirector/PDMR Shareholding
14th Oct 202511:51 amRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSAppointment of joint corporate broker
9th Oct 20251:53 pmRNSDirector/PDMR Shareholding
2nd Oct 20254:20 pmRNSTotal Voting Rights
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.